TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06359574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training
Description: The Core Competency Model (CCM; Cramer et al., 2013, 2019) is an evidence-based educational training program for BHCs in suicide prevention core suicide prevention skills. The ten core competencies are: (1) Manage personal attitudes and reactions to suicide; (2) Maintain a collaborative stance toward the client; (3) Elicit evidence-based risk and protective factors; (4) Focus on current suicide plan and intent of suicidal ideation; (5) Determine risk level; (6) Enact a collaborative evidence-based treatment plan; (7) Notify and involve other persons; (8) Document risk, plan, and reasoning for clinical decisions; (9) Know the law concerning suicide, and; (10) Engage in debriefing and self-care. The CCM will be adapted for this pilot trial. In light of the SDV problem in carceral settings, the CCM for Corrections (CCM-C; Cramer, Kaniuka, \& Peiper, 2022) was adapted to address both suicide and self-injury assessment, treatment, and prevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training
Description: The Core Competency Model (CCM; Cramer et al., 2013, 2019) is an evidence-based educational training program for BHCs in suicide prevention core suicide prevention skills. The ten core competencies are: (1) Manage personal attitudes and reactions to suicide; (2) Maintain a collaborative stance toward the client; (3) Elicit evidence-based risk and protective factors; (4) Focus on current suicide plan and intent of suicidal ideation; (5) Determine risk level; (6) Enact a collaborative evidence-based treatment plan; (7) Notify and involve other persons; (8) Document risk, plan, and reasoning for clinical decisions; (9) Know the law concerning suicide, and; (10) Engage in debriefing and self-care. The CCM will be adapted for this pilot trial. In light of the SDV problem in carceral settings, the CCM for Corrections (CCM-C; Cramer, Kaniuka, \& Peiper, 2022) was adapted to address both suicide and self-injury assessment, treatment, and prevention.
Study: NCT03887273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage
Study: NCT06140173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low osmolar contrast
Description: 100 mL of 350 mg omnipaque will be administered via nasogastric tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile water
Description: 100 mL of sterile water will be administered via nasogastric tube
Study: NCT06362317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg, intravenous infusion every 3 weeks until disease progression or occurrence of intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.
Study: NCT06266390

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
Study: NCT05159076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention to Increase Physical Activity
Description: The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time.
Study: NCT05825105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
Study: NCT06362317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: When the body weight is ≥60 kg, the dosage of Lenvatinib is 12mg qd, when body weight \< 60kg the dosage is 8mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemox Chemotherapy（Gemox or GC）
Description: Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemox Chemotherapy（Gemox or GC）
Description: Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1.
Study: NCT05263414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS
Description: tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tVNS
Description: tVNS allows the non-invasive activation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to promote GABA release. tVNS will be performed by using a CE marked tVNS device. It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
Study: NCT05825105

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
Study: NCT06213363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCR1672 tablet
Description: All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCR1672 tablet
Description: All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
Study: NCT06569836

Intervention type: OTHER
Group type: OTHER
Intervention: 12-week intervention
Description: Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)

Intervention type: OTHER
Group type: OTHER
Intervention: 12-week intervention
Description: Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)
Study: NCT04705246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
Study: NCT05358496

Intervention type: DIAGNOSTIC_TEST
Intervention: Data collection
Description: Clinical data collection

Intervention type: DIAGNOSTIC_TEST
Intervention: Data collection
Description: Clinical data collection
Study: NCT06113952

Intervention type: DEVICE
Intervention: Sharps bin to collect used needles/injections
Description: Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.

Intervention type: DEVICE
Intervention: Sharps bin to collect used needles/injections
Description: Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
Study: NCT06569836

Intervention type: OTHER
Group type: OTHER
Intervention: 12-week attention control
Description: The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
Study: NCT05064059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: favezelimab/pembrolizumab
Description: Coformulated favezelimab/pembrolizumab (800 mg/200 mg), IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: Oral
Study: NCT05586204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
Study: NCT05614037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine sustained release tablets (trade name: plendil®)
Description: Reference preparation (R) : Felodipine sustained release tablets (trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine Controlled Release Tablets
Description: Test preparation (T) :Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Usage: Oral, 1 tablet at a time, once a day. Take it before bed and swallow it with water. Do not break, press or chew the pill.
Study: NCT05586204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eligibility reminder
Description: Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link to a narrow set of vaccine venues
Description: The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link to a narrow set of vaccine venues
Description: The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
Study: NCT05064059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: Oral
Study: NCT06216392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study: NCT05692661

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton plus carbon ion radiotherapy
Description: CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
Study: NCT04212585

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test
Description: Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori
Study: NCT05299099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C006 inj.
Description: IN-C006 will be injected continuously for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCN301
Description: RCN301 will be injected continuously for 3 days.
Study: NCT05766371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Given IV
Study: NCT06565195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3962681
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3962681
Description: IT injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IT injection
Study: NCT06084195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample and tissue sample
Description: During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data
Study: NCT06008964

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ylang Ylang oil with inhalation
Description: Ylang Ylang OIL WILL BE INHALED

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender oil with inhalation
Description: LAVENDER OIL WILL BE INHALED
Study: NCT05857124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vielight Neuro RX Gamma active device
Description: The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vielight Neuro RX Gamma sham device
Description: The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
Study: NCT05357872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep anesthesia depth
Description: The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light anesthesia depth
Description: The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
Study: NCT05190042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotinuous suture
Description: Cotinuous suture using surgery thread

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clips
Description: Hemostatic clips
Study: NCT05684068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gum Graft Placed on Denuded Bone
Description: The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
Study: NCT06565195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IT injection